A Trial of TTA-121 on Autism Spectrum Disorder

Overview

To test efficacy and safety of a novel nasal spray of oxytocin on social deifies in autism spectrum disorder, and To compare effect sizes of different doses

Full Title of Study: “An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 16, 2020

Interventions

  • Drug: TTA-121
    • A nove intranasal spray of oxytocin and placebo

Arms, Groups and Cohorts

  • Other: Low dose once per day and placebo
    • Four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
  • Other: Low dose twice per day and placebo
    • Four weeks administrations of TTA-121 3U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
  • Other: High dose once per day and placebo
    • Four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
  • Other: High dose twice per day and placebo
    • Four weeks administrations of TTA-121 10U twice per day in morning and evening. After four weeks washout, four weeks administrations of placebo twice per day in morning and evening.
  • Other: Placebo and low dose once per day
    • Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U once per day in morning and placebo once per day in evening.
  • Other: Placebo and low dose twice per day
    • Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 3U twice per day in morning and evening.
  • Other: Placebo and high dose once per day
    • Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U once per day in morning and placebo once per day in evening.
  • Other: Placebo and high dose twice per day
    • Four weeks administrations of placebo twice per day in morning and evening. After four weeks washout, four weeks administrations of TTA-121 10U twice per day in morning and evening.

Clinical Trial Outcome Measures

Primary Measures

  • Efficacy on autism spectrum social core symptom assessed by social reciprocity score on the Autism Diagnostic Observation Schedule module 4
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration
    • Changes in social reciprocity score (range: 0-14, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period

Secondary Measures

  • Efficacy on autism spectrum core symptom assessed by communication score on the Autism Diagnostic Observation Schedule module 4
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration
    • Changes in communication score (range: 0-8, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period
  • Efficacy on autism spectrum core symptom assessed by repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration
    • Changes in repetitive and restricted behavior score (range: 0-10, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period
  • Efficacy on autism spectrum core symptom assessed by revised algorithm score of social affect on the Autism Diagnostic Observation Schedule module 4
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration
    • Changes in revised algorithm score of social affect (range: 0-20, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period
  • Efficacy on autism spectrum core symptom assessed by revised algorithm of repetitive and restricted behavior score on the Autism Diagnostic Observation Schedule module 4
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration
    • Changes in revised algorithm of repetitive and restricted behavior score (range: 0-10, Higher value represent a worth outcome) on Autism Diagnostic Observation Schedule module 4 between baseline and endpoint of each administration period
  • Efficacy assessed by Clinical Global Impression-Improvement
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration
    • Changes in Clinical Global Impression-Improvement (range: 1-7, Higher value represent a worse outcome) between baseline and endpoint of each administration period
  • Efficacy assessed by Clinical Global Impression-Severity
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration
    • Changes in Clinical Global Impression-Severity (range: 1-7, Higher value represent a worse outcome) between baseline and endpoint of each administration period
  • Efficacy assessed by Global Assessment of Functioning
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was assessed within 100 min after the last drug administration
    • Changes in Global Assessment of Functioning (range: 1-100, Higher value represent a better outcome) between baseline and endpoint of each administration period
  • Efficacy assessed by gaze fixation time on social region
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 60 min after the last drug administration
    • Changes in gaze fixation time on social region during being talked between baseline and endpoint of each administration period
  • Efficacy assessed by quantitative analysis of facial expression
    • Time Frame: At baseline, which was before and on the same day as the first administration, and at endpoint, which was started approximately 15 min after the last drug administration
    • Changes in quantitative measure of facial expression on videos recorded during ADOS administration between baseline and endpoint of each administration period

Participating in This Clinical Trial

Inclusion Criteria

1. Diagnosis of autism spectrum disorder based on Diagnostic and Statistical Manual of Mental Disorders-V with score exceeding the cut-off value of 10 for qualitative abnormalities in social reciprocity on Autism Diagnostic Interview Revised (ADIR) 2. Full scale Intelligent quotient above 80 as measured using the Wechsler Adult Intelligent Scale-III 3. Written informed consent for participating the trial Exclusion Criteria:

1. Diagnosis of bipolar disorder or schizophrenia spectrum disorder 2. Primary diagnosis of depressive disorders, obsessive-compulsive and related disorders, anxiety disorders, trauma- and stressor-related disorders, dissociative disorders, somatic symptom and related disorders, or neurodevelopmental disorders other than autism spectr um disorder 3. Instability in symptoms of comorbid mental disorders such as depressive disorders or anxiety disorders 4. History of changes in medication or doses of psychotropics within one month before registration 5. Current treatment with more than one psychotropics 6. History of hyper-sensitivity to oxytocin 7. History of seizures or traumatic brain injury with loss of consciousness for longer than 5 minutes 8. History of alcohol-related disorders, substance abuse, or addiction 9. Family history of male breast cancer 10. Subject who has severe complications 11. Known hypersensitivity to some drugs and foods 12. Subject who is not able to consent contraception during study period 13. Participation in another registration clinical trial and administration of investigational drug during 120 days before informed consent 14. Other Subjects whom a lead investigator or the patient's primary physician deems are not appropriate for this study

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 54 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hamamatsu University
  • Collaborator
    • Japan Agency for Medical Research and Development
  • Provider of Information About this Clinical Study
    • Principal Investigator: Hidenori Yamasue, M.D., Ph.D., Professor – Hamamatsu University
  • Overall Official(s)
    • Hidenori Yamasue, MD, PhD, Principal Investigator, Department of Psychiatry, Hamamatsu University School of Medicine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.